GlassScriptPhysician profile
Sorab Gupta
NPI 1972917656
$2,228.49
in general payments reported to CMS, 2019-2025
20 companies · $435 in 2025
The $435 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $91.39 · 2021: $673 · 2022: $673 · 2023: $32.34 · 2024: $323 · 2025: $435.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $361 · Consulting Fee: $350 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $361.19 |
| Consulting Fee | $350.00 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $488.03 | 2020-2022 | |
| Alexion Pharmaceuticals, INC. | $429.99 | 2024-2025 | Ultomiris, Soliris |
| Novartis Pharmaceuticals Corporation | $342.42 | 2021-2024 | |
| Tempus Ai, INC | $143.99 | 2024 | |
| Celgene Corporation | $123.26 | 2021-2025 | Reblozyl |
| Rigel Pharmaceuticals, INC. | $119.37 | 2022 | |
| Amgen INC. | $73.88 | 2021-2022 | |
| Genzyme Corporation | $69.27 | 2020-2021 | |
| Pharmacyclics LLC, An Abbvie Company | $68.04 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.90 | 2021-2023 | Gilotrif |
| Jazz Pharmaceuticals INC. | $55.17 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $43.81 | 2021-2024 | Opdivo |
| Foundation Medicine, INC. | $39.57 | 2022 | |
| Lilly USA, LLC | $32.20 | 2021 | |
| Merck Sharp & Dohme LLC | $31.25 | 2024 | Keytruda, Lynparza |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $27.16 | 2022 | |
| Genmab U.S., INC. | $26.69 | 2022 | |
| Aveo Pharmaceuticals, INC. | $19.23 | 2022 | |
| Pfizer INC. | $19.20 | 2022 | |
| Seagen INC. | $13.06 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sorab Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.